To date, the commercially available inhibitor of IL-6 receptor, tocilizumab, and a gp130 specific inhibitor, FE999301, are only available for the treatment of autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. The gene discussed is IL6ST; the disease is inflammatory bowel disease.